Resources

Guidance note for 'Testing of cannabis and cannabis resin' updated.

The Narcotic Drugs Amendment (Medicinal Cannabis) Regulations 2021 introduced a requirement for a review of the medicinal cannabis scheme to be undertaken.

Response to the report on the inquiry into the RMC Bill

The Australian Government response to the Inquiry into current barriers to patient access to medicinal cannabis has now been published.

On 11 October 2019, the Prime Minister, the Hon Scott Morrison MP, announced that the Australian Government is stepping up its commitment to the Pacific by launching the kava pilot program (pilot). The pilot involves the relaxation of kava related prohibited import regulations to allow Australians more access to kava and its benefits.

Presentation slides from the Kava pilot phase 2 design webinar on 4 November 2020.

Guideline to assist licence applicants and holders in designing and meeting security standards that are required for the cultivation, production and manufacture of medicinal cannabis.

Information on how the Office of Drug Control implements cost recovery for regulatory activities associated with the direct costs of processing licence and permit applications for the cultivation of medicinal cannabis and the ongoing monitoring and compliance of the regulatory scheme.

This form authorises the Office of Drug Control (Department of Health and Aged Care) to obtain information on an individual named in an application for the grant or variation of a licence under the Narcotic Drugs Act 1967.

A comprehensive review of the Medicinal Cannabis Cost Recovery Framework was undertaken in
late 2019 and early 2020. This paper presents the findings of that review.

The Government is inviting feedback on the proposal to implement a single medicinal cannabis licence under the Narcotic Drugs Act 1967 and other associated reforms to the licence application process.

Our plan for how HPRG will maintain and build its regulatory science capability over the next 5 years.

Example follow-up questions to assist applicants in preparing their medicinal cannabis licence applications.

Guideline to assist licence applicants and holders to assess whether they are fit and proper to hold a licence to cultivate, produce or manufacture medicinal cannabis and products.

Guideline to assist licence applicants and holders in designing and meeting standards required for record keeping and reporting matters related to cultivation, production and manufacture of medicinal cannabis.

Application form for a licence to export narcotic, psychotropic and precursor substances.

Information for applicants who intend to apply for a permit to export narcotic, psychotropic and precursor substances from Australia.

Review of the Narcotic Drugs Act 1967 - Final report authored by Professor John McMillan AO, published on 10 July 2019.

Information on how the Office of Drug Control implements cost recovery for regulatory activities.

A total of 50 submissions were received in response to the public consultation between 22 Feb to 22 March 2019. Read the published submissions.

The 2016 amendments to the ND Act included a requirement in section 26A that the Minister cause a review of the operation of the Act to be undertaken as soon as possible after the second anniversary of the commencement of the 2016 amendments.

The Australian Government is exploring the appropriate mechanism to increase the quantity of kava that may be imported into Australia by incoming passengers for personal use.

Update to guidance on sponsored import and supply of unregistered medicinal cannabis products.

Guidance on export of medicinal cannabis and products.

Policy Circular #03/17